Beijing Wenfeng Tianji Pharmaceutical Technology

Beijing Wenfeng Tianji Pharmaceutical Technology is a Chinese biopharmaceutical company specializing in the development of innovative small molecule therapeutics for dermatological diseases. The company is most notable for the development of Benvitimod (also known as Tapinarof), a first-in-class non-steroidal topical treatment that acts as an Aryl hydrocarbon receptor (AhR) agonist. Benvitimod was approved by China's National Medical Products Administration (NMPA) in 2019 for the treatment of mild-to-moderate plaque psoriasis, marking a significant advancement in topical psoriasis therapy. Following its acquisition by Fosun Pharma in 2016, the company operates as a key subsidiary within Fosun's pharmaceutical innovation portfolio, focusing on expanding the clinical applications of its lead asset.